Who Owns Leucovorin?
Leucovorin (folinic acid, also known as citrovorum factor or 5-formyltetrahydrofolate) is a generic prescription drug with no single brand owner. It was originally developed by Lederle Laboratories (a division of American Cyanamid) in the late 1940s and early 1950s. Leucovorin is now manufactured by multiple pharmaceutical companies including Pfizer (through its Hospira injectable drug business), Teva Pharmaceutical Industries, Fresenius Kabi, and other generic manufacturers. It is a critical component of standard colorectal cancer chemotherapy regimens including FOLFOX and FOLFIRI.
Parent Company
Pfizer
Founded
1952
Status
Publicly Traded
Headquarters
Multiple manufacturers (generic drug)
Who Owns Leucovorin?
- Parent Company: Pfizer
- Ownership Type: Product line
- Company Type: Publicly Traded
- Stock Ticker: NYSE: PFE
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Leucovorin | Pfizer | Product line |
History of Leucovorin
- Founded: 1952
- Founders: Lederle Laboratories (American Cyanamid) - original developer
Leucovorin's history begins with the broader scientific discovery of folic acid and its role in cellular metabolism. Folic acid (vitamin B9) was isolated and characterized in the 1940s, and researchers quickly recognized its essential role in nucleotide synthesis and cell division. The discovery of folic acid antagonists, including aminopterin and methotrexate, as anticancer agents in the late 1940s by Sidney Farber at Boston Children's Hospital created the need for a rescue agent that could reverse the toxic effects of these antifolate drugs on normal tissues.
Leucovorin (folinic acid, 5-formyltetrahydrofolate) is a reduced, active form of folic acid that can bypass the enzyme dihydrofolate reductase (DHFR), which is inhibited by methotrexate. By providing cells with a form of folate that does not require DHFR for activation, leucovorin can rescue normal cells from methotrexate toxicity without significantly reducing the drug's antitumor effect, because cancer cells take up methotrexate more avidly than normal cells and are more dependent on DHFR activity.
Lederle Laboratories, a pharmaceutical division of American Cyanamid Company headquartered in Pearl River, New York, developed leucovorin calcium as a pharmaceutical product in the late 1940s and early 1950s. Lederle was one of the leading pharmaceutical companies in the United States at the time, with expertise in vitamins, antibiotics, and other pharmaceutical products. The FDA approved leucovorin calcium injection in 1952, establishing it as a prescription drug for the prevention and treatment of methotrexate toxicity and for the treatment of megaloblastic anemia due to folic acid deficiency.
The clinical applications of leucovorin expanded significantly over subsequent decades. In the 1970s and 1980s, oncologists discovered that leucovorin could enhance the antitumor activity of fluorouracil (5-FU), a widely used chemotherapy drug for colorectal cancer and other solid tumors. Leucovorin stabilizes the ternary complex formed between 5-FU's active metabolite (fluorodeoxyuridine monophosphate, FdUMP), the enzyme thymidylate synthase (TS), and the reduced folate cofactor, inhibiting TS more effectively and enhancing 5-FU's cytotoxic effect. This discovery led to the widespread use of leucovorin as a biochemical modulator of 5-FU in colorectal cancer chemotherapy.
The development of combination chemotherapy regimens for colorectal cancer in the 1990s and 2000s established leucovorin as an essential component of standard treatment. The FOLFOX regimen (leucovorin, fluorouracil, and oxaliplatin) and the FOLFIRI regimen (leucovorin, fluorouracil, and irinotecan) became the standard first-line and second-line treatments for metastatic colorectal cancer, respectively. These regimens are used in hundreds of thousands of patients worldwide each year, making leucovorin one of the most widely used drugs in oncology.
Lederle Laboratories was acquired by American Home Products Corporation (later renamed Wyeth) in 1994 as part of a broader consolidation of the pharmaceutical industry. Wyeth continued to manufacture and market leucovorin under the Lederle brand. Pfizer acquired Wyeth in 2009 for approximately $68 billion, bringing the Lederle pharmaceutical business, including leucovorin manufacturing, into the Pfizer portfolio. Pfizer subsequently acquired Hospira, a major manufacturer of injectable drugs, in 2015 for approximately $17 billion, further consolidating its injectable drug manufacturing capabilities.
As leucovorin's patents expired long ago, the drug has been manufactured by numerous generic pharmaceutical companies for decades. The generic leucovorin market is characterized by multiple competing manufacturers, price competition, and periodic supply shortages when manufacturing disruptions affect one or more suppliers. The FDA's drug shortage database has listed leucovorin calcium injection as a shortage drug on multiple occasions, reflecting the challenges of maintaining consistent supply of a critical oncology drug manufactured by a limited number of suppliers.
LevoLeucovorin (also known as levoleucovorin or l-leucovorin, the active levo isomer of leucovorin) is a more recent development, marketed under the brand name Fusilev by Spectrum Pharmaceuticals. Levoleucovorin contains only the pharmacologically active levo isomer of leucovorin, compared to the racemic mixture in conventional leucovorin, and is approved for the same indications as leucovorin at half the dose.
About Pfizer
What does Pfizer own?
Pfizer owns a portfolio of prescription medicines and vaccines spanning oncology, cardiovascular, immunology, vaccines, and rare diseases. Key products include Eliquis (blood thinner), Prevnar (pneumococcal vaccine), Ibrance (breast cancer), Vyndaqel (rare heart disease), Paxlovid (COVID-19 antiviral), and Comirnaty (COVID-19 vaccine, with BioNTech). The 2023 acquisition of Seagen added oncology antibody-drug conjugates including Padcev, Adcetris, and Tukysa.
Is Pfizer publicly traded?
Yes, Pfizer Inc. is listed on the New York Stock Exchange under ticker PFE. The company has been publicly traded since 1944. Pfizer has no single controlling shareholder, with major institutional holders including Vanguard Group, BlackRock, and State Street. Pfizer is a component of the Dow Jones Industrial Average and the S&P 500.
Who founded Pfizer?
Pfizer was founded in 1849 in Brooklyn, New York by Charles Pfizer and his cousin Charles Erhart. Charles Pfizer was a German-born chemist who emigrated to the United States. The company's first product was santonin, an antiparasitic agent. Pfizer's breakthrough into modern pharmaceuticals came during World War II when the company developed large-scale penicillin production.
Where is Pfizer headquartered?
Pfizer is headquartered in New York City, New York, USA. The company maintains its principal executive offices in Midtown Manhattan. Pfizer operates manufacturing facilities in the United States, Belgium, Ireland, the United Kingdom, Germany, Japan, China, India, and Brazil, and sells products in more than 125 countries worldwide.
How many products does Pfizer sell?
Pfizer sells dozens of prescription medicines and vaccines across multiple therapeutic areas. The company's portfolio includes products in oncology, vaccines, cardiovascular, immunology, rare diseases, and hospital products. More than a dozen of Pfizer's products each generate over $1 billion in annual revenue. The company's research pipeline includes hundreds of compounds in various stages of clinical development.
Who owns Pfizer?
Pfizer Inc. is publicly traded on the NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. Major institutional shareholders include Vanguard Group, BlackRock, and State Street. Albert Bourla serves as Chairman and CEO. Pfizer has no founding family or private equity controlling shareholder.
- Founded: 1849
- Headquarters: New York, New York, USA
- Company Type: Publicly Traded
- Stock: NYSE: PFE
- Revenue: approximately $63.6 billion (FY2025)
- Employees: Approximately 88,000
Where Is Leucovorin Made / Based?
- Headquarters: Multiple manufacturers (generic drug)
- Manufacturing / Operations: United States, Europe, India
Leucovorin Sustainability & Ethics
Leucovorin manufacturing and distribution involves significant environmental and ethical considerations typical of the pharmaceutical industry. As a generic oncology drug manufactured by multiple companies worldwide, leucovorin production requires stringent quality control, environmental compliance, and ethical business practices.
Pharmaceutical Manufacturing Sustainability: Major leucovorin manufacturers including Pfizer, Teva Pharmaceutical Industries, and Fresenius Kabi have implemented comprehensive sustainability programs in their manufacturing facilities. These initiatives focus on reducing energy consumption, water usage, and waste generation in injectable drug production. Pfizer has committed to achieving carbon neutrality across its operations by 2040, while Teva aims to source 100% renewable electricity for its manufacturing sites by 2025.
Supply Chain Ethics and Quality Assurance: The leucovorin supply chain involves multiple stakeholders from API manufacturers in China and India to finished product manufacturers in the United States, Europe, and Israel. All major manufacturers adhere to Good Manufacturing Practices (GMP) and implement rigorous quality control systems to ensure product safety and efficacy. The concentration of API manufacturing in specific geographic regions creates supply chain vulnerabilities that manufacturers address through diversified sourcing strategies and inventory management.
Environmental Impact of Injectable Drug Production: Leucovorin calcium injection production requires sterile manufacturing environments, cleanroom facilities, and specialized packaging that generate significant environmental impact. Manufacturers have implemented programs to reduce plastic waste in vial and packaging materials, improve energy efficiency in cleanroom operations, and minimize water usage in sterilization processes. Pfizer's Hospira division and Fresenius Kabi have both invested in greener manufacturing technologies for their injectable drug portfolios.
Access to Essential Medicines: As an essential component of standard colorectal cancer chemotherapy regimens, leucovorin represents a critical medicine for cancer treatment globally. The generic nature of leucovorin helps maintain affordability compared to branded oncology drugs, though periodic drug shortages have highlighted access challenges. Manufacturers work with healthcare organizations and government agencies to maintain stable supply and prevent treatment disruptions for cancer patients.
Clinical Research Ethics: Leucovorin's development and clinical use followed established ethical standards for pharmaceutical research. The drug's original development by Lederle Laboratories occurred during an era of expanding clinical research ethics, and its subsequent integration into standard chemotherapy regimens has been supported by extensive clinical trial evidence. Contemporary use of leucovorin in clinical trials continues to follow institutional review board (IRB) oversight and informed consent requirements.
Awards & Recognition
Leucovorin itself, as a generic drug, does not receive commercial awards or recognition. However, its role in cancer treatment has been recognized through the medical and scientific community's acknowledgment of its importance in oncology therapy.
Clinical Significance Recognition: Leucovorin's integration into the FOLFOX and FOLFIRI chemotherapy regimens has contributed to these protocols being recognized as standard of care treatments for metastatic colorectal cancer. These regimens have been endorsed by major oncology organizations including the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO).
Research Contributions: The development of leucovorin as a biochemical modulator of fluorouracil represents an important advancement in combination chemotherapy principles. This scientific contribution has been recognized through numerous citations in medical literature and inclusion in clinical practice guidelines worldwide. The mechanism of leucovorin's action in enhancing 5-FU efficacy serves as a model for rational drug combination development in oncology.
Historical Pharmaceutical Achievement: The original development of leucovorin by Lederle Laboratories in the 1950s represents an important milestone in supportive cancer care. The drug's ability to enable high-dose methotrexate chemotherapy while protecting normal cells expanded treatment possibilities for various cancers, contributing to improved patient outcomes in multiple cancer types.
Generic Drug Industry Recognition: Leucovorin serves as an example of successful generic drug competition that maintains treatment accessibility while ensuring quality. Multiple manufacturers including Pfizer/Hospira, Teva Pharmaceutical Industries, and Fresenius Kabi have received recognition for maintaining consistent supply of this critical oncology drug despite manufacturing challenges and market dynamics.
Leucovorin Recalls & Controversies
Leucovorin has faced several significant challenges related to drug shortages and supply disruptions, though major product recalls have been limited. The drug's critical role in cancer treatment has made supply disruptions particularly concerning for healthcare providers and patients.
Drug Shortages (2008-2023): Leucovorin calcium injection has experienced multiple drug shortages documented by the FDA and American Society of Health-System Pharmacists (ASHP). These shortages have occurred due to various factors including manufacturing delays, quality control issues, and increased demand. Notable shortage periods include 2008-2009, 2011-2012, 2018, and 2021-2022. During these shortages, healthcare providers have implemented rationing protocols, prioritized patients for treatment, and sometimes substituted levoleucovorin (Fusilev) at significantly higher cost.
Manufacturing Quality Issues: Several manufacturers have faced temporary production interruptions due to quality control concerns. In 2019, a major manufacturer voluntarily held production to address sterility testing concerns, though no contaminated products reached the market. These quality control measures, while disrupting supply, demonstrate the industry's commitment to patient safety.
Pricing Controversy: The price differential between conventional leucovorin and levoleucovorin (Fusilev) has generated controversy in oncology practice. Levoleucovorin's price can be 10-20 times higher than generic leucovorin, despite offering only modest theoretical advantages. This pricing disparity has raised questions about value-based pricing in oncology supportive care drugs and has led some healthcare systems to implement policies favoring conventional leucovorin except in specific clinical situations.
Supply Chain Concentration Concerns: The concentration of leucovorin API manufacturing in limited geographic areas, primarily China and India, has raised concerns about supply chain resilience. Regulatory scrutiny of API manufacturing facilities and international trade tensions have periodically created uncertainty about supply stability. These concerns have prompted discussions about onshoring critical pharmaceutical manufacturing capabilities.
Clinical Practice Guidelines: Controversies have occasionally arisen regarding optimal leucovorin dosing and scheduling in chemotherapy regimens. Different oncology organizations have occasionally published varying recommendations, though consensus guidelines generally align on standard dosing protocols. These clinical practice discussions reflect the ongoing effort to optimize leucovorin use in cancer treatment.
Brands Owned by Pfizer
Leucovorin Ownership: Pros & Cons
Advantages
- +Leucovorin's generic status, with multiple competing manufacturers, ensures broad availability and low cost compared to branded oncology drugs, making it accessible to patients and healthcare systems globally, including in low- and middle-income countries where branded oncology drugs may be unaffordable
- +The drug's essential role as a component of the FOLFOX and FOLFIRI colorectal cancer regimens, which are the standard of care for metastatic colorectal cancer worldwide, ensures sustained demand regardless of competitive dynamics in the broader oncology market
- +Leucovorin's dual mechanism of action, both as a methotrexate rescue agent and as a biochemical modulator of fluorouracil, makes it a versatile component of multiple chemotherapy protocols across different cancer types, including colorectal cancer, breast cancer, head and neck cancer, and others
- +The drug's long history of clinical use, dating to its FDA approval in 1952, has generated an extensive evidence base for its safety and efficacy across multiple indications, supporting its continued use as a standard component of chemotherapy protocols
- +The availability of leucovorin in both injectable (intravenous and intramuscular) and oral formulations provides flexibility for use in different clinical settings, from inpatient high-dose methotrexate rescue to outpatient colorectal cancer chemotherapy
Considerations
- -Leucovorin calcium injection has been subject to periodic drug shortages in the United States, reflecting the challenges of maintaining consistent supply of a critical oncology drug manufactured by a limited number of suppliers, with manufacturing disruptions at one or more suppliers capable of creating significant supply constraints
- -The commodity nature of the leucovorin market, with multiple generic manufacturers competing primarily on price, creates ongoing pressure on manufacturer margins and may reduce incentives for investment in manufacturing capacity expansion or quality improvements
- -The availability of levoleucovorin (Fusilev) as a branded alternative to conventional leucovorin, at a significantly higher price, creates a competitive dynamic in the methotrexate rescue and 5-FU modulation markets that may affect the market share of conventional leucovorin in some settings
- -Leucovorin's use as a component of FOLFOX and FOLFIRI regimens means that its demand is tied to the continued use of these regimens as standard colorectal cancer treatments; the development of new chemotherapy regimens that do not include leucovorin could reduce demand
- -The concentration of active pharmaceutical ingredient (API) manufacturing for leucovorin in China and India creates supply chain risks related to geopolitical events, regulatory actions, or natural disasters that could disrupt API supply and affect the availability of finished leucovorin products
Frequently Asked Questions About Leucovorin
Sources & Further Reading
- FDA Drug Shortages Database -
- American Society of Health-System Pharmacists Drug Shortages -
- National Comprehensive Cancer Network Guidelines -
- Pfizer Oncology Product Information -
- Teva Pharmaceutical Oncology Portfolio -
- Fresenius Kabi Oncology Products -
- PubMed Literature Search: Leucovorin FOLFOX FOLFIRI -
- American Society of Clinical Oncology Guidelines -
- European Medicines Agency Leucovorin Information -
- FDA Press Release: Leucovorin Approval for Cerebral Folate Transport Deficiency -
- Pfizer Corporate Responsibility Report 2025 -
- Fresenius Kabi Sustainability Report -
Where to Buy
Disclosure: We may earn commission from purchases
Leucovorin on AmazonCompetitors to Leucovorin
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Novartis | Switzerland | 2015 | Specialty | Global | Unisex | |
| Kenvue | USA | 1974 | Mass market | Global | All-ages | |
| Haleon | United Kingdom | 1976 | Mass market | Global | All-ages | |
| Novartis | Switzerland | 2009 | Mass market | Global | All-ages | |
| Takeda | Japan | 2018 | Mass market | Europe | All-ages | |
| Merck | USA | 2008 | Mass market | Global | All-ages |
Learn More About Competitors
Cosentyx
Owned by Novartis
Prescription biologic medication for treating autoimmune diseases including psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, and other inflammatory conditions.
Motrin
Owned by Kenvue
American brand of ibuprofen pain relief medication owned by Kenvue, the consumer health spinoff from Johnson & Johnson, which is being acquired by Kimberly-Clark in a $40 billion deal announced in November 2025.
Voltaren
Owned by Haleon plc
Over-the-counter anti-inflammatory pain relief brand containing diclofenac, owned by Haleon plc (LSE/NYSE: HLN) since its July 2022 spinoff from the GSK and Pfizer consumer health joint venture, with Voltaren growing mid-single digit in full-year 2025 supported by new format patches and Voltadexibu launches.
Afinitor
Owned by Novartis
Prescription oncology medication for treating various cancers including renal cell carcinoma and breast cancer, manufactured and marketed by Novartis.
Alofisel
Owned by Unknown Company
Prescription cell therapy for treating complex perianal fistulas in Crohn's disease, manufactured and marketed by Takeda Pharmaceutical Company.
Bridion
Owned by Merck & Co.
Prescription medication for reversing neuromuscular blockade during anesthesia, manufactured and marketed by Merck & Co.
Competitive Analysis
Market Positioning: Leucovorin competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Pfizer Stock Information
Jobs at Pfizer
Latest News About Leucovorin
Related Articles About Leucovorin
View more articles
Pfizer vs Johnson & Johnson: Pharma Brand Portfolios Compared
Pfizer and Johnson & Johnson are two of the most recognizable names in healthcare. But their brand portfolios look nothing alike. Here is a complete breakdown of what each company owns, how they got there, and what sets them apart.
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Brand Spin-offs: When Companies Sell Off Their Own Brands
From Kenvue to Kellanova, major corporations are spinning off iconic brands into independent companies. Learn why, how it works, and what it means for consumers.
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Activase
Prescription thrombolytic medication for treating acute myocardial infarction and stroke, manufactured and marketed by Roche.
Acuvue
Johnson & Johnson's contact lens brand, launched in 1988 as the world's first disposable contact lens and now the global market leader in daily disposable lenses.
Adcetris
Prescription antibody-drug conjugate for treating Hodgkin lymphoma and other CD30-positive lymphomas, manufactured and marketed by Takeda Pharmaceutical Company.